Literature DB >> 36187527

Chondroblastic Variant of Osteosarcoma Mandible-an Intent to Cure.

Sakthi Usha Devi J1, Prasanna Srinivasa Rao1, Balamurugan T D1, Muhammed Owaise J1.   

Abstract

Osteosarcoma is one of the rarer malignancies that affects the facial skeletal structures. There are only a few retrospective studies discussing the management and outcomes of this malignancy due to the rarity of the disease. Unlike osteosarcoma of long bones, this malignancy has more incidence in patients in the older age group leading to difficulty in the management of this condition but with better outcomes due to the contrasting behavior of this malignancy. Osteosarcoma of the mandible has a longer median survival rate and lesser incidence of distant metastases. Osteosarcomas are more common in the appendicular skeleton, with the most prevalent sites being in the distal femur. Osteosarcoma of the mandible is a rare occurrence with management most commonly being a surgical intervention. Here, we present a 52-year-old female patient who was diagnosed to have osteosarcoma of the mandible treated with hemimandibulectomy and right sternocleidomastoid flap reconstruction with the final histopathology report as osteosarcoma-chondroblastic subtype.
© The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2022.

Entities:  

Keywords:  Mandible; Oncology; Osteosarcoma; Surgery

Year:  2022        PMID: 36187527      PMCID: PMC9515304          DOI: 10.1007/s13193-022-01495-w

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  12 in total

1.  Osteosarcoma of the jaws: factors influencing prognosis.

Authors:  Megan Granowski-LeCornu; Sung-Kiang Chuang; Leonard B Kaban; Meredith August
Journal:  J Oral Maxillofac Surg       Date:  2011-02-01       Impact factor: 1.895

2.  Well-differentiated osteosarcoma of the jaw bones: a clinicopathologic study of 15 cases.

Authors:  Elizabeth G Demicco; Vikram Deshpande; G Petur Nielsen; Susan V Kattapuram; Andrew E Rosenberg
Journal:  Am J Surg Pathol       Date:  2010-11       Impact factor: 6.394

3.  Multidisciplinary management of head and neck sarcomas.

Authors:  R James Colville; Fraser Charlton; Charles G Kelly; Jonathan J Nicoll; Neil R McLean
Journal:  Head Neck       Date:  2005-09       Impact factor: 3.147

4.  Osteosarcoma of the jaw: an analysis of a series of 74 cases.

Authors:  María Luisa Paparella; Liliana Graciela Olvi; Daniel Brandizzi; Alicia Keszler; Eduardo Santini-Araujo; Rómulo Luis Cabrini
Journal:  Histopathology       Date:  2013-07-26       Impact factor: 5.087

5.  Clinical and histopathological profile of primary or secondary osteosarcoma of the jaws.

Authors:  Francesca Angiero; Francesca Moltrasio; Giorgio Cattoretti; Maria Gabriella Valente
Journal:  Anticancer Res       Date:  2011-12       Impact factor: 2.480

Review 6.  Osteosarcoma of the jaw bones.

Authors:  M L Chindia
Journal:  Oral Oncol       Date:  2001-10       Impact factor: 5.337

7.  Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database.

Authors:  Benjamin J Miller; Peter Cram; Charles F Lynch; Joseph A Buckwalter
Journal:  J Bone Joint Surg Am       Date:  2013-07-03       Impact factor: 5.284

8.  Statistical observation of osteosarcoma of the maxillofacial region in Japan. Analysis of 114 Japanese cases reported between 1930 and 1989.

Authors:  H Tanzawa; S Uchiyama; K Sato
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1991-10

9.  Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment.

Authors:  B Ashleigh Guadagnolo; Gunar K Zagars; A Kevin Raymond; Robert S Benjamin; Erich M Sturgis
Journal:  Cancer       Date:  2009-07-15       Impact factor: 6.860

10.  Interdisciplinary combined treatment of craniofacial osteosarcoma with neoadjuvant and adjuvant chemotherapy and excision of the tumour: a retrospective study.

Authors:  Oliver C Thiele; Kolja Freier; Claire Bacon; Gerlinde Egerer; Christof M Hofele
Journal:  Br J Oral Maxillofac Surg       Date:  2008-04-23       Impact factor: 1.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.